Scholarlink

Background <p>This retrospective study aimed to characterize the clinical, radiographic, and biochemical outcomes of surgical hip dislocation (SHD) combined with intralesional curettage and bone grafting for the treatment of phosphaturic mesenchymal tumors (PMT) of the femoral head and neck.</p> Methods <p>A total of 7 patients with PMT of the femoral head and neck confirmed by pathology (mean lesion length 18.8&#xa0;mm) were treated in our hospital between January 2018 and December 2023. All patients underwent SHD combined with tumor curettage and bone grafting. Preoperative and postoperative assessments included radiographs/MRI for union, recurrence, avascular necrosis (Steinberg grade), secondary osteoarthritis (Tönnis grade), and clinical outcomes by visual analog scale (VAS), Musculoskeletal Tumor Society scoring system (MSTS) and modified Harris Hip Score (mHHS).</p> Results <p>All patients underwent SHD with intralesional curettage and bone grafting. Over a mean 42-month follow-up, no local recurrence or distant metastasis occurred. All graft sites achieved radiographic union. The Tönnis grade remained unchanged in six patients, whereas one patient showed progression from grade 1 to grade 2. The same patient also showed progression of femoral head osteonecrosis from Steinberg stage 0 to stage I. Pain and functional scores improved at the final follow-up: median VAS decreased from 4.0 to 1.0, median MSTS increased from 18.0 to 27.0, and median mHHS improved from 75.0 to 85.0. Serum phosphate levels improved postoperatively and normalized during follow-up.</p> Conclusion <p>SHD combined with intralesional curettage and bone grafting may represent a viable hip-preserving treatment option for patients with PMT involving the femoral head and neck. However, these findings warrant further validation in larger cohorts with longer follow-up periods.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Surgical hip dislocation for the phosphaturic mesenchymal tumor of the femoral head and neck: a clinical outcome analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Yanlin Zhou,
  • Yacheng Li,
  • Xibei Liao,
  • Lu Wang,
  • Xianzhe Tang,
  • Xianghong Zhang,
  • Tang Liu

摘要

Background

This retrospective study aimed to characterize the clinical, radiographic, and biochemical outcomes of surgical hip dislocation (SHD) combined with intralesional curettage and bone grafting for the treatment of phosphaturic mesenchymal tumors (PMT) of the femoral head and neck.

Methods

A total of 7 patients with PMT of the femoral head and neck confirmed by pathology (mean lesion length 18.8 mm) were treated in our hospital between January 2018 and December 2023. All patients underwent SHD combined with tumor curettage and bone grafting. Preoperative and postoperative assessments included radiographs/MRI for union, recurrence, avascular necrosis (Steinberg grade), secondary osteoarthritis (Tönnis grade), and clinical outcomes by visual analog scale (VAS), Musculoskeletal Tumor Society scoring system (MSTS) and modified Harris Hip Score (mHHS).

Results

All patients underwent SHD with intralesional curettage and bone grafting. Over a mean 42-month follow-up, no local recurrence or distant metastasis occurred. All graft sites achieved radiographic union. The Tönnis grade remained unchanged in six patients, whereas one patient showed progression from grade 1 to grade 2. The same patient also showed progression of femoral head osteonecrosis from Steinberg stage 0 to stage I. Pain and functional scores improved at the final follow-up: median VAS decreased from 4.0 to 1.0, median MSTS increased from 18.0 to 27.0, and median mHHS improved from 75.0 to 85.0. Serum phosphate levels improved postoperatively and normalized during follow-up.

Conclusion

SHD combined with intralesional curettage and bone grafting may represent a viable hip-preserving treatment option for patients with PMT involving the femoral head and neck. However, these findings warrant further validation in larger cohorts with longer follow-up periods.